Who is sponsoring NCT01902836?

NCT01902836 is sponsored by National Polytechnic Institute, Mexico.

What drugs are being tested in NCT01902836?

Interventions in NCT01902836: Conventional treatment plus DLE, Conventional treatment plus placebo.

What condition does NCT01902836 study?

NCT01902836 studies Childhood Atopic Dermatitis.

Is NCT01902836 still recruiting?

NCT01902836 is currently completed. Last updated 26 July 2013.

Last reviewed 2013-07-26 · How we verify

NCT01902836

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Human Dialyzed Leukocytes Extracts in Paediatrics Patients With Moderate Atopic Dermatitis.

Completed Phase 2 Last updated 26 July 2013

What this trial tests

Phase 2 trial testing Conventional treatment plus DLE in Childhood Atopic Dermatitis in 58 participants. Completed in 1 January 2013.

Timeline

1 August 2011

Primary endpoint
1 December 2012

1 January 2013

Quick facts

Lead sponsor	National Polytechnic Institute, Mexico
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	58
Start date	1 August 2011
Primary completion	1 December 2012
Estimated completion	1 January 2013
Sites	1 location across Mexico

Drugs / interventions tested

Conventional treatment plus DLE — full drug profile →
Conventional treatment plus placebo — full drug profile →

Conditions studied

Childhood Atopic Dermatitis — all drugs for Childhood Atopic Dermatitis →

Sponsor

National Polytechnic Institute, Mexico

Who can join

Adults 2 to 17, any sex, with Childhood Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Clinical outcome evaluated by SCORAD
Time frame: Day 14
To determine clinical outcome by SCORAD.

Sponsor's own description

Patients with atopic dermatitis treated with conventional treatment plus Dialyzed Leukocyte Extracts (DLE-oral Transferon) as adjuvant, have better clinical outcome than patients treated only with conventional treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other National Polytechnic Institute, Mexico trials

Trials by the same sponsor.

NCT06597370 — Immunogenicity Induced by COVID-19 Vaccines in Mexican Population · completed
NCT04112251 — Effects of COcoa Supplement in OBese Adolescent Subjects · NA · completed
NCT06502808 — Hyperbaric Oxygen Therapy in Diabetic Foot · completed
NCT06703086 — Gene Modulation of NLRP3, IL-1β and TNF-α in Peripheral Blood of Patients With Exogenous Obesity Treated With Berberine · NA · completed
NCT06426966 — Gymnema Sylvestre vs Berberine in Obesity Gene Expression of Adipokines · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01902836 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Polytechnic Institute, Mexico
Last refreshed: 26 July 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01902836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing